Kathy Ford Email

Chief Operating Officer . Kura Oncology

Current Roles

Employees:
153
Revenue:
$5.7M
About
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Our pipeline consists of small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Our lead drug candidate is tipifarnib, a farnesyl transferase inhibitor, which is currently being studied in multiple Phase 2 clinical trials in solid tumor and hematologic indications. Our pipeline also includes KO-947, an ERK inhibitor, currently in a Phase 1 dose-escalation trial, and KO-539, a menin-MLL inhibitor, currently in preclinical development. For additional information, please visit our website at www.kuraoncology.com.
Kura Oncology Address
12730 High Bluff Drive
San Diego, CA
United States
Kura Oncology Email

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.